Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0KV1Q
|
|||
| Former ID |
DCL001020
|
|||
| Drug Name |
Trafermin
|
|||
| Synonyms |
Fiblast; Fiblast (TN); Trafermin (genetical recombination); Trafermin (USAN/INN); Trafermin (genetical recombination) (JAN)
Click to Show/Hide
|
|||
| Indication | Periodontitis [ICD-11: DA0C; ICD-10: K05.4; ICD-9: 523.5] | Phase 3 | [1] | |
| Company |
Johnson & Johnson Licensee; Kaken Pharmaceutical
|
|||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fibroblast growth factor receptor 2 (FGFR2) | Target Info | Activator | [1] |
| KEGG Pathway | MAPK signaling pathway | |||
| Ras signaling pathway | ||||
| Rap1 signaling pathway | ||||
| Endocytosis | ||||
| PI3K-Akt signaling pathway | ||||
| Signaling pathways regulating pluripotency of stem cells | ||||
| Regulation of actin cytoskeleton | ||||
| Pathways in cancer | ||||
| Prostate cancer | ||||
| Central carbon metabolism in cancer | ||||
| NetPath Pathway | IL1 Signaling Pathway | |||
| Panther Pathway | FGF signaling pathway | |||
| Pathway Interaction Database | FGF signaling pathway | |||
| Reactome | Activated point mutants of FGFR2 | |||
| WikiPathways | Regulation of Actin Cytoskeleton | |||
| Ectoderm Differentiation | ||||
| Hair Follicle Development: Organogenesis (Part 2 of 3) | ||||
| Hair Follicle Development: Induction (Part 1 of 3) | ||||
| Cardiac Hypertrophic Response | ||||
| Signaling Pathways in Glioblastoma | ||||
| Neural Crest Differentiation | ||||
| Signaling by FGFR | ||||
| MicroRNAs in cardiomyocyte hypertrophy | ||||
| Angiogenesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.